Curis Lifesciences IPO Date, Review, Price, Allotment Details
Curis Lifesciences IPO will open for subscription on November 7, 2025, and close on November 11, 2025. It is a Book Built Issue, through which the company aims to raise approximately ₹27.52 crores, comprising a fresh issue worth ₹27.52 crores and an offer for sale of up to [.] equity shares with a face value of ₹10 each.
The price band for the Curis Lifesciences IPO has been set at ₹120 to ₹128 per share. The quota distribution includes 35% for retail investors, 50% for QIBs, and 15% for HNIs. The IPO is scheduled to be listed on the NSE on November 14, 2025, while the allotment date is November 12, 2025.
Financially, the company has shown steady growth — reporting revenue of ₹49.65 crores in FY 2025, up from ₹35.87 crores in FY 2024, and a profit of ₹6.11 crores in 2025, compared to ₹4.87 crores in 2024. Based on these financials, analysts suggest that the IPO could be a good option for long-term investors.
Curis Lifesciences IPO Details
Curis Lifesciences IPO Market Lot
The minimum market lot for the Curis Lifesciences IPO is 2,000 shares, requiring an application amount of ₹2,56,000.
IPO Reservation
Curis Lifesciences IPO Anchor Investors
Curis Lifesciences IPO Dates
The Curis Lifesciences IPO will open on November 7 and close on November 11, 2025. The allotment is scheduled to be finalized on November 12, and the IPO will be listed on the NSE on November 14, 2025.
Promoters and Holding Pattern
The promoters of the company are Mr. Dharmesh Dashrathbhai Patel, Mr. Siddhant Jayantibhai Pawasia, Mr. Piyush Gordhanbhai Antala and Mr. Jaimik Mansukhbhai Patel.
Objects of the Issue & Utilisation of Proceeds
About Curis Lifesciences IPO
Curis Lifesciences Limited, established in 2010, is a leading pharmaceutical company engaged in manufacturing a diverse range of products, including tablets, capsules, external preparations, oral liquids, and sterile ophthalmic ointments. The company procures ready-made goods from manufacturers and distributes them to wholesalers and clients across India. As of July 31, 2025, Curis Lifesciences employed 95 permanent staff members.
The company manufactures medicines both in India and internationally under contract or licensing agreements, as well as for its own brand. It serves over 100 corporate clients, in addition to its two proprietary brand clients in Yemen and Kenya. Curis Lifesciences also operates a state-of-the-art manufacturing facility in Sanand, Gujarat, where stringent quality control measures ensure that every product meets the highest standards of safety and efficacy.
Curis Lifesciences IPO Company Financial Report
Amount ₹ in Crores
Curis Lifesciences IPO Valuation – FY2025
Check Curis Lifesciences IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
IPO Lead Managers aka Merchant Bankers
- Finaax Capital Advisors Private Limited
Company Address
Curis Lifesciences Ltd.
PF-23, GIDC Sanand – II,
Industrial Estate,
Sanand
Ahmedabad, Gujarat, 382110
Phone: +91 99045 22543
Email: cs@curisls.com
Website: https://curisls.com/
IPO Registrar
MUFG Intime India Pvt.Ltd.
Phone: +91-22-4918 6270
Email: curislifesciences.smeipo@in.mpms.mufg.com
Website: https://in.mpms.mufg.com/Initial_Offer/public-issues.html